Search This Blog

Friday, November 20, 2026

Scorpion Capital obefazimod safety allegations drive Abivax ADRs down

 


  • Scorpion Capital published a November 20 short report targeting lead drug obefazimod.
  • The report alleged carcinogenicity risks, extreme lipophilicity and unsupported drug science.
  • Abivax opened roughly 2% lower, then losses deepened after report circulation.
  • The 9.24% decline was nearly twice Abivax's recent average daily range.
  • Reuters and Investing.com linked the intraday selloff directly to Scorpion's report.
  • Scorpion disclosed a short position and financial interest in Abivax declining.
  • Abivax's 4:33 p.m. statement rejected the allegations as inaccurate and misleading.
  • The post-close rebuttal confirmed the catalyst but did not cause regular-session losses.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.